About Cryoport, Inc
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee. Address: 112 Westwood Place, Brentwood, TN, United States, 37027
Cryoport, Inc News and around…
Latest news about Cryoport, Inc (CYRX) common stock and company :
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -55% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months ended March 31, 2022.
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended March 31, 2022 (first quarter 2022) on Thursday, May 5, 2022 after U.S. markets close.
The Nashville-area company expanded into Houston when it acquired Houston-based Cryogene Partners in 2019.
The firm stores and moves temperature-controlled specimens for customers in biopharmaceuticals, animal husbandry, reproductive medicine, government agencies and more.
The deal follows a string of international buys over the past two years for Cryoport, which most recently bought Brussels-based F-Airgate in May.
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has acquired Cell&Co BioServices, headquartered in Clermont-Ferrand, France with additional operations in Pont-du-Château, France. Founded in 2012, Cell&Co is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. Its accreditations include ISO 9001, ANSM (Inves
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its New Prague facility has returned to full production. As previously announced, a fire occurred in a portion of the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota on January 25, 2022, causing production to be temporarily curtailed. The New Prague facility manufactures aluminum dewars
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has unanimously authorized a repurchase program, under which Cryoport may repurchase up to $100 million of its outstanding common stock and/or convertible senior notes.
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -780% and 2.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months and year ended December 31, 2021.
CryoPort, Inc. (CYRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, February 24, 2022 after U.S. markets close.
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today provided an update on resumption of activities at the New Prague facility. As previously announced, a fire occurred in a portion of the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota on January 25, 2022, causing production to be temporarily curtailed. The New Prague facility manufactures aluminum dewa
Investment company abrdn plc (Current Portfolio) buys Coca-Cola Co, Globant SA, Stanley Black & Decker Inc, CenterPoint Energy Inc, LPL Financial Holdings Inc, sells JPMorgan Chase, Procter & Gamble Co, Medtronic PLC, L3Harris Technologies Inc, Bristol-Myers Squibb Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, abrdn plc.
Investment company First Bank & Trust (Current Portfolio) buys Daktronics Inc, Amgen Inc, Bristol-Myers Squibb Co, Realty Income Corp, British American Tobacco PLC, sells Pfizer Inc, Canadian Imperial Bank of Commerce, Cisco Systems Inc, , Electronic Arts Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Bank & Trust.
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today reports that on January 25, 2022, a fire occurred at the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota. The New Prague facility manufactures aluminum dewars and is one of MVE Biological Solutions' three global manufacturing facilities. There were no injuries reported and damage was limited to a porti
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has entered into a strategic partnership with Cell Matters, S.A. to deliver to the life sciences industry end-to-end cryopreservation services for leukapheresis derived therapies supporting both autologous and allogeneic cell therapies. The companies will jointly develop the commercial approach for marketing these se
Cryoport, Inc (CYRX) is a NASDAQ Common Stock listed in Common Stock, Industrials, Integrated Freight & Logistics
